TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02660775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: schizophrenia
Description: The battery (ClaCoS) is composed by 6 tests and several scores will be recorded for each:~* for emotion perception : Facial emotions recognition task (TREF)~* for theory of mind : Movie for the assessment of social cognition ( MASC-VF)~* for attributional bias : Ambiguous Intentions Hostility Questionnaire ( AIHQ)~* for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~* for empathy :Questionnaire of cognitive and affective empathy ( QCAE) for people with schizophrenia~* for self assessment : Self - assessment of social cognition (ACSo)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism
Description: The battery (ClaCoS ) is composed by 6 tests and several scores will be recorded for each:~* for emotion perception : Facial emotions recognition task(TREF ): total score, score per emotion, detection levels~* for theory of mind : Movie for the assessment of social cognition (MASC ) :total score, error type~* for attributional bias : Ambiguous Intentions Hostility Questionnaire (AIHQ) :hostility score, attribution score, aggression score~* for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~* for empathy : Empathy quotient (EQ)~* for self assessment : Self - assessment of social cognition ( ACSo ): total score and scores per processes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy controls
Description: only social cognitive measures
Study: NCT01826032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care for OSA
Description: sleep higiene and dietary counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care for OSA
Description: sleep higiene and dietary counseling
Study: NCT04020614

Intervention type: OTHER
Intervention: Survey
Description: A survey with 13 questions will be applied to the patients
Study: NCT01894919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® vaccine (1 dose at study month zero)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® vaccine (1 dose at study month zero)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® vaccine (2 doses 1 month apart)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® vaccine (2 doses 1 month apart)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® vaccine (2 doses 1 month apart)
Study: NCT03492515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin
Description: If platelet count \<30×10\^9/L and with haemorrhage or risk of bleeding,the patients began to receive subcutaneous injection of TPO with the dose of 300 Unit/kg qd,duration ≤14 days;If platelet count is between 30×10\^9/L and 50×10\^9/L, the dose will be 300 Unit/kg qod;If platlet count ≥100×109/L, stop this treatment;After delivery, if platelet count \<30×10\^9/L and with haemorrhage or risk of bleeding,subcutaneous injection of TPO with the dose of 300 Unit/kg qd or qod will be given at a duration ≤14 days;If platelet count is between 30×10\^9/L and 50×10\^9/L, the dose will be 300 Unit/kg qw;If platlet count ≥100×109/L, stop the treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Concentrate
Description: according to the their conditions, use if necessary
Study: NCT02762669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 10-7mol/L to 10-5mol/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 10-7mol/L to 10-5mol/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 10-7mol/L to 10-5mol/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 10-7mol/L to 10-5mol/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 10-7mol/L to 10-5mol/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 10-7mol/L to 10-5mol/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 10-7mol/L to 10-5mol/L
Study: NCT00367601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg qd days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg IV, day 1
Study: NCT03208738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VetChange
Description: VetChange is a self-management mobile application designed to to concurrently reduce both alcohol misuse and PTSD symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VetChange
Description: VetChange is a self-management mobile application designed to to concurrently reduce both alcohol misuse and PTSD symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based drinking assessment and feedback tool (AFT)
Description: Program will administer a comprehensive assessment of drinking and consequences of drinking, and will provide normative feedback and highlight negative consequences of drinking.
Study: NCT00797667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant 140 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant 280 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 140 mg telcagepant placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg telcagepant placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 280 mg telcagepant placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 280 mg telcagepant placebo
Study: NCT01969071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: The effects of levosimendan on renal function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Standard Inotropic agent
Study: NCT04245488

Intervention type: OTHER
Group type: OTHER
Intervention: taste test
Description: rate intensity of sour solutions and fatty acid solutions
Study: NCT02621970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 1
Description: Cisplatin 25 mg/m2, D1-3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 2
Description: Cisplatin 100 mg/m2, D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60mg/m2, D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: Intensity-modulated radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Intensity-modulated radiotherapy
Study: NCT02187016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirFloss + BreathRx
Description: Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirFloss + Listerine
Description: Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
Study: NCT04688554

Intervention type: BEHAVIORAL
Intervention: Behavioral tests
Description: Behavioral tests may include one or more of the following procedures: Upper extremity testing, Perdue Peg Board testing, Hand tactile detection and discrimination test, Temperature and pain threshold testing, Lower extremity Testing, Myomotion Inertial Motion Testing.

Intervention type: BEHAVIORAL
Intervention: Behavioral tests
Description: Behavioral tests may include one or more of the following procedures: Upper extremity testing, Perdue Peg Board testing, Hand tactile detection and discrimination test, Temperature and pain threshold testing, Lower extremity Testing, Myomotion Inertial Motion Testing.
Study: NCT01238523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long leg cast in full extension
Description: Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long leg cast with 45 degrees of flexion
Description: Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
Study: NCT04755426

Intervention type: BEHAVIORAL
Intervention: AVITA--Aortic Valve Improved Treatment Approaches
Description: AVITA is an interactive shared decision making tool that helps patients clarify their treatment goals and preferences and communicate those preferences to their valve specialist.

Intervention type: BEHAVIORAL
Intervention: AVITA--Aortic Valve Improved Treatment Approaches
Description: AVITA is an interactive shared decision making tool that helps patients clarify their treatment goals and preferences and communicate those preferences to their valve specialist.
Study: NCT00924573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride (HOE490)
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride (HOE490)
Description: oral administration
Study: NCT01913769

Intervention type: RADIATION
Intervention: Thallium-201 Myocardial Perfusion Study
Description: One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
Study: NCT04059900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STW5 (Iberogast®, BAY98-7411)
Description: The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
Study: NCT04849858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Participants in this group will receive a TAP block using the drug Bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine followed by a re-dosing during their hospitalization
Study: NCT02132936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100 aerosol foam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aerosol foam vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol BDP gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gel vehicle
Study: NCT04512105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT03145558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirapazamine
Description: Replacing the standard chemotherapy agent doxorubicin used in TACE with tirapazamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Standard of care for TACE
Study: NCT04311723

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia Procedure
Description: Receive anesthesia using laryngeal mask

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia Procedure
Description: Receive anesthesia using endotracheal tube

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Undergo standard of care bronchoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Undergo standard of care bronchoscopy
Study: NCT04166851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP campaign messages developed via open contest
Description: PrEP campaign messages will be developed via an open contest in Baltimore.
Study: NCT02187016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Floss
Description: Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning used once daily.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: Manual Toothbrush used twice daily, 1 minute.
Study: NCT04166851

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PrEP campaign messages developed via social marketing approach
Description: PrEP campaign messages developed with a traditional social marketing approach.
Study: NCT04699721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5
Description: 3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)
Study: NCT05131282

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test of PE risk
Description: A blood test is applied to women between 11weeks and 13 weeks+6 days of GA at the first visit to evaluate risk of developing PE

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test of PE risk
Description: A blood test is applied to women between 11weeks and 13 weeks+6 days of GA at the first visit to evaluate risk of developing PE

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test of Preterm PE risk
Description: A blood test is applied to women between 11 weeks and 13 weeks+6 days of GA at the first visit to evaluate risk of developing Preterm PE

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test of Preterm PE risk
Description: A blood test is applied to women between 11 weeks and 13 weeks+6 days of GA at the first visit to evaluate risk of developing Preterm PE
Study: NCT02204839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal insulin dose
Study: NCT04061655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Isomaltoside 1000
Description: Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
Study: NCT02080624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Topical Rapamycin
Description: After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study.~A medical history, which involves questions about your health history, any medications you are taking or plan to take, any allergies and the treatments you received for your CM.~A physical exam, during which you will be asked about any problems that you might be having. Additionally, your clinician will check your vital signs (blood pressure, heart rate, weight and height). The doctor will also evaluate your performance status, which indicates how much your illness affects your activity level.~Blood tests, which will be done to make sure your hemogram, triglyceride and cholesterol levels are normal.~A pregnancy test for females will be done to check that you are not pregnant. If theses tests show that you are eligible to participate in the research study, you will begin the study treatment.
Study: NCT00682097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: Escalating oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: Escalating oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: Escalating oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: Escalating oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: Escalating oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: Escalating oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: Escalating oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral doses
Study: NCT02883361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Description: Counseling meant to enhance motivation and decrease ambivalence about change, including asking open-ended questions, eliciting change-talk, and identifying discrepancies between current behaviour and valued behaviour

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: Having participants come into the lab and fill out questionnaires with a researcher in-person
Study: NCT00682097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral doses
Study: NCT03759301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormones Somatropin Recombinant
Description: Growth Hormones Somatropin Recombinant 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline solution
Description: same volume as growth hormone ampule used
Study: NCT00563706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vabicaserin
Description: This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01477346

Intervention type: OTHER
Group type: OTHER
Intervention: Nurse intervention
Description: Complex package of care involving patient information and advice concerning lifestyle modification and recommended drug therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Continuing standard General Practitioner led care.
Study: NCT04453319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Wound Closure and dressing
Description: Femoral Wound Closure and dressing
Study: NCT02389478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrums
Description: rubbing drops of colostrum inside a baby's cheeks using a sterile syringe

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oropharyngeal administration of Normal saline
Description: rubbing drops of Normal saline inside a baby's cheeks using a sterile syringe
Study: NCT01281488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorescence imaging
Description: Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorescence imaging
Description: Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system
Study: NCT03726372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: rocuronium is a neuromuscular blocking agent with a duration of 40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: rocuronium is a neuromuscular blocking agent with a duration of 40 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous infusion
Description: rocuronium is continuously infused
Study: NCT01281488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorescence imaging
Description: Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system
Study: NCT03726372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermittent injection
Description: rocuronium is intermittently given
Study: NCT00569972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Capsules, 15 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Capsules, 30 mg, 3 capsules each night before bedtime; Duration - Visit 3-7 for 28 days
Study: NCT01281488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorescence imaging
Description: Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorescence imaging
Description: Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: Undergo standard approach robot-assisted laparoscopic partial nephrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: Undergo standard approach robot-assisted laparoscopic partial nephrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: Undergo standard approach robot-assisted laparoscopic partial nephrectomy
Study: NCT00631709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CareLink Remote Monitoring
Description: Substitution of CareLink Remote Monitoring of Pacemakers for in-clinic pacemaker follow-up visits